ESTRO 2025 - Abstract Book

S1386

Clinical - Lung

ESTRO 2025

Keywords: Relapse, Salvage therapy, Survival

References: 1) Westeel V et al. Lancet Oncol 2022;23(9):1180-1188

2) Evison M et al. Clin Oncol (R Coll Radiol) 2021 Mar; 33(3):145-154 3) Martini N et al. J Thorac Cardiovasc Surg 1995 Jan; 109(1):120-9 4) Rulach R et al. Clin Oncologies (R Coll Radiol) 2018 Feb;30(2):101-109

3240

Digital Poster SABR One Stop Service for early lung cancer: same-day sim-plan-and-treat single fraction stereotactic ablative radiotherapy Neil D Wallace 1 , Brigid Moran 2 , Thomas Devereux 3 , Mark Burns 3 , Adam Yeo 4 , Nicholas Hardcastle 4,5,6 , Vanessa Panettieri 4,5 , Katrina Woodford 2 , Jasleen Kaur 2 , Jo Barber 2 , Lewis Lee 2 , Janelle Diery 2 , Bianca deDios 7 , Mary Duffy 8 , Michael MacManus 1,5 , Nikki Plumridge 1,5 , Mark Shaw 1,5 , Shankar Siva 1,5 , Susan Harden 1,5 1 Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 2 Department of Radiation Therapy, Peter, Melbourne, Australia. 3 Department of Radiation Therapy, Peter MacCallum Cancer Centre, Melbourne, Australia. 4 Department of Physical Science, Peter MacCallum Cancer Centre, Melbourne, Australia. 5 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. 6 Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia. 7 Department of Radiation Oncology Research, Peter MacCallum Cancer Centre, Melbourne, Australia. 8 Department of Nursing, Peter MacCallum Cancer Centre, Melbourne, Australia Purpose/Objective: Stereotactic Ablative Radiotherapy (SABR) is treatment of choice for most medically inoperable patients with early stage lung cancer (ELC) since the TROG 09.02 CHISEL trial (1). Randomized phase II trials have demonstrated non inferiority for single-fraction SABR (SFSABR) vs fractionated SABR for ELC (2,3), as did the TROG 13.01 SAFRON II trial for pulmonary metastases (4). We hypothesised that with modern planning technology and coordinated multi disciplinary teamwork, we could develop a quality assured one day service for planning and delivering curative intent SFSABR and that this service might benefit people who are elderly, frail, or living in rural/remote areas. Aims The purpose of this study is to demonstrate the technical feasibility and patient acceptability of same day SFSABR for ELC Material/Methods: This is a single centre prospective study. Participants: 10 patients with ELC deemed treatable with SFSABR by the Lung MDM will be recruited and undergo CT simulation, planning and delivery of 30Gy/1fx SFSABR within 8 hours. Design: Technical rapid workflow feasibility will be determined by recorded timings along the whole simulation, planning, QA and treatment delivery process, chart round peer review and multidisciplinary team feedback. Participant acceptability will be determined with nursing support by patient feedback through a short experience survey, completed within 2 weeks of SFSABR. Study endpoints -Technical: Proportion where time from commencement of planning CT to completion of treatment is <8 working hours. -Patient acceptability: Participant feedback and proportion reporting high overall satisfaction